Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Nektar Therapeutics Jumped 23% Higher in March

By Cory Renauer - Apr 8, 2018 at 11:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Updated plans for this biotech's burgeoning pipeline gave investors reason to smile.

What happened

Shares of Nektar Therapeutics (NKTR 2.31%), a mid-sized biotech developing novel drugs to address unmet needs, had another great month. It rose 22.8% in March, according to data from S&P Global Market Intelligence. The company's fourth-quarter earnings call contained a couple of positive updates that encouraged investors to push the stock.

So what 

The company shared some positive results from a kidney cancer trial with NKTR-214, an experimental immune-response simulator that appears to work well with Opdivo from Bristol-Myers Squibb (BMY -1.87%). In February, the big pharma signed a gargantuan deal that leaves Nektar eligible for $1.78 billion in various milestones plus 65% of any global profits that emerge from the tie-up. Updated results from 14 kidney cancer patients treated with the combination suggest there could be a lot of profits to split down the road.

Person drawing an upward sloping chart in the air with their fingers.

Image source: Getty Images.

In November, Nektar showed us an early 46% response rate among a small group of kidney cancer patients treated with NKTR-214 in combination with Opdivo. That response rate had risen to 57% in January, and an additional couple of patients brought the response rate to 71%, with all responses confirmed.

Nektar also announced plans to submit an application package for a chronic pain candidate with limited abuse potential. NKTR-181 aced a back-pain study last year and a pivotal human-abuse liability trial, both of which will support an application package that management plans to submit in the second quarter.

Now what

Demand for effective pain relief with low abuse potential is as strong as ever. If Nektar earns approval to market its painkiller specifically as an abuse-deterrent solution, blockbuster sales probably wouldn't be far behind.

On the oncology front, Incyte's unfortunate epacadostat failure makes NKTR-214 a lot more attractive to Bristol-Myers and several peers that have drugs like Opdivo that could use a boost. Nektar and Bristol will begin trials expected to enroll around 15,000 patients across nine tumor types. If positive results keep rolling in, expect more deep-pocketed drugmakers to come calling with open checkbooks.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nektar Therapeutics Stock Quote
Nektar Therapeutics
$3.54 (2.31%) $0.08
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$76.14 (-1.87%) $-1.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.